- ENPP1 Q121 variant, increased pulse pressure and reduced insulin signaling, and nitric oxide synthase activity in endothelial cellsSimonetta Bacci
Endocrine Unit, IRCCS Casa Sollievo della Sofferenza, Viale Cappuccini 1, San Giovanni Rotondo, Italy
Arterioscler Thromb Vasc Biol 29:1678-83. 2009..The genetic background of these 3 cardiovascular risk factors might be partly common. The ENPP1 K121Q polymorphism is associated with insulin resistance and cardiovascular risk...
- The K121Q polymorphism of the ENPP1/PC-1 gene is associated with insulin resistance/atherogenic phenotypes, including earlier onset of type 2 diabetes and myocardial infarctionSimonetta Bacci
Unit of Endocrinology, CSS Scientific Institute, San Giovanni Rotondo, Italy
Diabetes 54:3021-5. 2005..In conclusion, the ENPP1/PC-1 121Q variant is associated with a progressive deterioration of the IR-atherogenic phenotype; among diabetic individuals, it is also associated with earlier onset of type 2 diabetes and MI...
- Tag polymorphisms at the A20 (TNFAIP3) locus are associated with lower gene expression and increased risk of coronary artery disease in type 2 diabetesWatip Boonyasrisawat
Section on Genetics and Epidemiology, Joslin Diabetes Center, One Joslin Place, Boston, MA 02215, USA
Diabetes 56:499-505. 2007..04 and 0.028, respectively). These findings point to variability in the A20/TNFAIP3 gene as a modulator of CAD risk in type 2 diabetes. This effect is mediated by allelic differences in A20 expression...
- A visfatin promoter polymorphism is associated with low-grade inflammation and type 2 diabetesYuan Yuan Zhang
Research Division, Joslin Diabetes Center, Boston, Massachusetts 02215, USA
Obesity (Silver Spring) 14:2119-26. 2006..Our findings suggest that the visfatin/PBEF gene may play a role in determining T2D susceptibility, possibly by modulating chronic, low-grade inflammatory responses...
- Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variationCraig Pace
Centre for Clinical Immunology and Biomedical Statistics, 2nd Floor, North Block, Royal Perth Hospital, Wellington Street, Perth 6000, Western Australia
J Virol 80:9259-69. 2006..These data indicate that APOBEC3G-induced HIV-1 hypermutation represents a potent host antiviral factor in vivo and that the APOBEC3G-vif interaction may represent a valuable therapeutic target...
- Association of hGrb10 genetic variations with type 2 diabetes in Caucasian subjectsRosa Di Paola
Diabetes Care 29:1181-3. 2006
- Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistanceDavid Nolan
Clin Infect Dis 42:408-10. 2006
- HIV/AIDS. HIV: experiencing the pressures of modern lifeDavid Nolan
Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, Western Australia 6000, Australia
Science 307:1422-4. 2005
- Impact of host genetics on HIV disease progression and treatment: new conflicts on an ancient battlegroundDavid Nolan
AIDS 18:1231-40. 2004
- Metabolic complications associated with HIV protease inhibitor therapyDavid Nolan
Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, Western Australia, Australia
Drugs 63:2555-74. 2003....
- Tumour necrosis factor-alpha gene -238G/A promoter polymorphism associated with a more rapid onset of lipodystrophyDavid Nolan
Centre for Clinical Immunology and Biomedical Statistics, and Department of Clinical Immunology and Biochemical Genetics, Royal Perth Hospital, Perth, Western Australia
AIDS 17:121-3. 2003